B lymphocytopenia in rheumatoid arthritis is associated with the DRB1 shared epitope and increased acute phase response

Table 2 Disease-modifying antirheumatic drug usage in CD19_high and CD19_low patients in the prospective study cohort.

	CD19_high patients (n = 33)	CD19_low patients (n = 37)
Disease duration (years)	6.54	6.68
MTX at time of analysis [n (%)]	26 (78.8)	30 (81.1)
MTX dose (mg) [mean (range)]	15.4 (15–20)	16.1 (15–20)
MTX in combination with cyclosporine A	2	3
Duration of MTX therapy (months)	40.1	43.3
MTX-treated patients positive for SE [n (%)]	22 (66.7)	19 (51.3)
Tauredon therapy	1	2
Cyclosporine A	1	1
Chloroquine	2	0
Prednisolone at time of analysis (mg)	4.8	4.8
Dose range (mg)	3–10	3–7

MTX, methotrexate; SE, DRB1 shared epitope. Comparison of patients below and above the mean of the study population (110 cells/ml, CD19_high and CD19_low patients, respectively)of the prospective study cohort. The number of patients receiving the indicated disease-modifying antirheumatic drugand the dose ranges are presented. None of the comparisons show statistically significant differences.

ISSN: 1478-6362